The recent increases recorded by stocks launched on the market in recent years have fueled the market hype for recent IPOs. Among these, 2 biotech stocks stand out.
Among the new IPOs launched in recent years, there are some promising companies, that have taken a back seat due to the bearish winds of the stock market started in 2022. Many predict that with the strong recovery in 2023 and its continuation into 2024, it could be a good time to revisit recent initial public offerings.
Among these, there are 2 biotech companies which have recorded significant returns in recent weeks.
Why follow the biotechnology market?
The biotech sector is at the center of numerous innovations which, over time, could become real revolutions.
The healthcare market segment, as many know, is seen as an evergreen by investors, and the prices of stock indices linked to the health field have consistently recorded new highs for decades. For this and other reasons, the application of technological solutions to the healthcare field has strong potential, although according to many, still unexpressed.
A reference index for the market is represented by the Nasdaq Biotechnology, which aims to replicate the global performance of shares in the biotechnology field.
So why look at IPOs? Many promising companies are considering listing in this little-covered market segment to acquire capital from the market.
Among the most discussed recent IPOs are Nurix Therapeutics (NRIX) and Cerus (CERS).
Nurix Therapeutics (NRIX)
It focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company still has poorly consolidated and loss-making balance sheets and was launched on the Nasdaq in 2020, has a market capitalization of $726.08 million and the NRIX share price has grown in the last week by 18%. The company’s upcoming presentation at the annual meeting of the American Association for Cancer Research (AACR) has however sparked investor enthusiasm.
Cerus (CERS)
Cerus is a biomedical products company focused on the development and commercialization of the INTERCEPT Blood System, a proprietary biological replication control technology designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Over the past week, CERS stock price has risen by more than 20%, after the company reported strong fourth-quarter earnings.
Original article published on Money.it Italy 2024-03-12 14:53:56. Original title: Queste due IPO nel campo biotech stanno esplodendo
